Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

Recruiting now · Phase 2

Conditions studied: Interstitial Lung Disease, Pulmonary Fibrosis

In brief

The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).

Key facts

Study ID

NCT07572383

Run by

Peter Caravan

People needed

15

Starts

2026-05-14

Expected to finish

2028-12-31

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD.
• Starting immunosuppression treatment with mycophenolate mofetil, mycophenolate sodium, and / or prednisone for clinically indicated non-IPF ILD treatment.
• Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on high-resolution computed tomography (HRCT) performed within 1 year to or at Visit 1.
• Forced vital capacity (FVC) of >/= 45% and diffusing capacity of the lungs for carbon monoxide (DLCO) >/= 25% predicted on PFTs performed at Visit 1.

You may not qualify if…

• Current or prior exposure to FDA approved anti-fibrotic therapy.
• Extent of emphysema greater than extent of fibrosis.
• Pregnancy or plans to become pregnant at baseline or during follow-up.
• Contraindications to MRI.
• Contraindications to receiving gadolinium-based contrast agents.
• Research-related radiation exposure exceeds 50 millisievert (mSv) in the prior year.
• Estimated glomerular filtration rate (eGFR) < 30 mL/min (only for individuals with a history of chronic kidney disease).
• Clinically significant pulmonary hypertension (PH) defined by use of pulmonary vasodilatory therapy.
• Respiratory infection within the prior 6 weeks.
• Smoking of any kind within the prior 6 months.

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.